For severe manifestations of pediatric systemic lupus erythematosus (pSLE), including lupus nephritis, first line therapy has been the combination of corticosteroids with cyclophosphamide or azathioprine. However, prognosis remains poor and treatments have significant side effects. Studies in adults demonstrated that mycophenolate mofetil (MMF) was equivalent to cyclophosphamide in treating lupus nephritis; pediatric data were limited to small case series with heterogeneous disease manifestations.¹

To examine the safety and efficacy of MMF in pSLE.

Retrospective study at 2 hospitals in the United Kingdom.